Na skróty
Rozpocznij rozmowę z konsultantem Wyślij swoje pytanie
Money.plGiełda w Money.plKomunikaty ze spółekKomunikaty ze świata
Wiadomości ze spółek na świecie (ang.)
Data Państwo Firma Typ informacji Tytuł
2012-05-16 14:05:00 Norway Algeta ASA Updated survival results from phase III trial of Alpharadin (radium-223 chloride) in castration-resistant prostate cancer (CRPC) to be presented as Late-Breaking Abstract at ASCO 2012 Updated survival results from phase III trial of Alpharadin (radium-223 chloride) in castration-resistant prostate cancer (CRPC) to be presented as Late-Breaking Abstract at ASCO 2012
2012-05-14 08:00:00 Norway Algeta ASA Algeta to Present at Forthcoming Life Sciences Investor Conferences Algeta to Present at Forthcoming Life Sciences Investor Conferences
2012-05-03 14:56:00 Norway Algeta ASA CORRECTION: Algeta reports results for the first quarter 2012 CORRECTION: Algeta reports results for the first quarter 2012
2012-05-03 07:01:00 Norway Algeta ASA Algeta reports results for the first quarter 2012 Algeta reports results for the first quarter 2012
2012-04-30 08:01:00 Norway Algeta ASA Algeta and Sanofi extend research collaboration evaluating thorium-conjugated tumor-targeting antibody Algeta and Sanofi extend research collaboration evaluating thorium-conjugated tumor-targeting antibody
2012-04-23 08:00:00 Norway Algeta ASA Algeta schedules first quarter 2012 results presentation, webcast and conference call Algeta schedules first quarter 2012 results presentation, webcast and conference call
2012-04-19 19:11:00 Norway Algeta ASA Annual General Meeting held in Algeta ASA Annual General Meeting held in Algeta ASA
2012-04-12 08:01:00 Norway Algeta ASA Algeta exercises option to co-promote Alpharadin in the United States Algeta exercises option to co-promote Alpharadin in the United States
2012-03-29 13:00:00 Norway Algeta ASA Algeta ASA - Notice of Annual General Meeting 2012 Algeta ASA - Notice of Annual General Meeting 2012
2012-03-15 08:00:00 Norway Algeta ASA Algeta to Present at Forthcoming Life Sciences Investor Conferences Algeta to Present at Forthcoming Life Sciences Investor Conferences
2012-02-22 08:00:00 Norway Algeta ASA Algeta to Present at Forthcoming Life Sciences Investor Conferences Algeta to Present at Forthcoming Life Sciences Investor Conferences
2012-02-13 19:34:00 Norway Algeta ASA 2011 Annual Report for Algeta ASA 2011 Annual Report for Algeta ASA
2012-02-10 07:00:00 Norway Algeta ASA Analysis of updated ALSYMPCA phase III data confirms overall survival benefit of Alpharadin in castration-resistant prostate cancer patients with bone metastases Analysis of updated ALSYMPCA phase III data confirms overall survival benefit of Alpharadin in castration-resistant prostate cancer patients with bone metastases
2012-02-09 07:00:00 Norway Algeta ASA Algeta results for the fourth quarter 2011 and full year 2011 Algeta results for the fourth quarter 2011 and full year 2011
2012-02-02 14:56:00 Norway Algeta ASA Expanded Access Program for investigational drug Alpharadin (radium-223 chloride) initiated in the United States Expanded Access Program for investigational drug Alpharadin (radium-223 chloride) initiated in the United States
2012-02-01 08:00:00 Norway Algeta ASA Algeta schedules fourth quarter 2011 results presentation, webcast and conference call Algeta schedules fourth quarter 2011 results presentation, webcast and conference call
2012-02-01 00:01:00 Norway Algeta ASA Detailed results from ALSYMPCA phase III study highlight the positive impact of Alpharadin on skeletal-related events associated with bone metastases from castration-resistant prostate cancer Detailed results from ALSYMPCA phase III study highlight the positive impact of Alpharadin on skeletal-related events associated with bone metastases from castration-resistant prostate cancer
2012-01-27 08:00:00 Norway Algeta ASA Detailed results from ALSYMPCA phase III study with Alpharadin to be presented at 2012 Genitourinary Cancers Symposium (Abstracts #8 and #9) Detailed results from ALSYMPCA phase III study with Alpharadin to be presented at 2012 Genitourinary Cancers Symposium (Abstracts #8 and #9)
2012-01-17 07:55:00 Norway Algeta ASA Jeffrey W. Albers appointed President of Algeta US Jeffrey W. Albers appointed President of Algeta US
2012-01-05 08:01:00 Norway Algeta ASA Algeta President & CEO Andrew Kay to present at the 30th Annual J.P. Morgan Healthcare Conference Algeta President & CEO Andrew Kay to present at the 30th Annual J.P. Morgan Healthcare Conference
2011-12-09 14:00:00 Norway Algeta ASA Positive phase IIa bone marker data of Alpharadin in breast cancer patients with bone metastases presented at 2011 San Antonio Breast Cancer Symposium Positive phase IIa bone marker data of Alpharadin in breast cancer patients with bone metastases presented at 2011 San Antonio Breast Cancer Symposium
2011-12-06 08:00:00 Norway Algeta ASA Positive phase IIa bone marker data of Alpharadin in breast cancer patients with bone metastases to be presented at 2011 San Antonio Breast Cancer Symposium Positive phase IIa bone marker data of Alpharadin in breast cancer patients with bone metastases to be presented at 2011 San Antonio Breast Cancer Symposium
2011-11-10 07:01:00 Norway Algeta ASA Algeta results for the third quarter 2011 Algeta results for the third quarter 2011
2011-11-07 08:00:00 Norway Algeta ASA Algeta's Financial Calendar 2012 Algeta's Financial Calendar 2012
2011-10-31 08:00:00 Norway Algeta ASA Algeta schedules third quarter 2011 results presentation, webcast and conference call Algeta schedules third quarter 2011 results presentation, webcast and conference call
2011-10-18 08:00:00 Norway Algeta ASA Leading Experts in Prostate Cancer Treatment to Present at Algeta R&D Days Leading Experts in Prostate Cancer Treatment to Present at Algeta R&D Days
2011-09-26 08:00:00 Norway Algeta ASA Algeta to Host Investor Meeting, Webcast and Conference Call to Discuss Positive Phase III Trial Results for Alpharadin Algeta to Host Investor Meeting, Webcast and Conference Call to Discuss Positive Phase III Trial Results for Alpharadin
2011-09-24 00:04:00 Norway Algeta ASA Alpharadin Significantly Improves Overall Survival for Patients with Castration-Resistant Prostate Cancer and Symptomatic Bone Metastases Alpharadin Significantly Improves Overall Survival for Patients with Castration-Resistant Prostate Cancer and Symptomatic Bone Metastases
2011-09-14 08:00:00 Norway Algeta ASA Algeta to Present at Forthcoming Life Sciences Investor Conferences Algeta to Present at Forthcoming Life Sciences Investor Conferences
2011-09-13 08:00:00 Norway Algeta ASA Alpharadin Phase III Trial Data to be presented at Best and Late-Breaking Session at the 2011 European Multidisciplinary Cancer Congress Alpharadin Phase III Trial Data to be presented at Best and Late-Breaking Session at the 2011 European Multidisciplinary Cancer Congress
2011-09-08 08:00:00 Norway Algeta ASA Algeta appoints Mike Booth as Senior Vice President, Communications and Corporate Affairs Algeta appoints Mike Booth as Senior Vice President, Communications and Corporate Affairs
2011-08-23 08:00:00 Norway Algeta ASA FDA Grants Fast Track Designation to Alpharadin for the Treatment of Castration-Resistant Prostate Cancer Patients with Bone Metastases FDA Grants Fast Track Designation to Alpharadin for the Treatment of Castration-Resistant Prostate Cancer Patients with Bone Metastases
2011-08-11 07:01:00 Norway Algeta ASA Algeta results for the first half and second quarter 2011 Algeta results for the first half and second quarter 2011
2011-08-01 08:00:00 Norway Algeta ASA Algeta schedules second quarter 2011 results presentation, webcast and conference call Algeta schedules second quarter 2011 results presentation, webcast and conference call
2011-06-22 08:00:00 Norway Algeta ASA Algeta awarded grant to develop new tumor-targeted alpha-pharmaceuticals based on Thorium Algeta awarded grant to develop new tumor-targeted alpha-pharmaceuticals based on Thorium
2011-06-07 07:00:00 Norway Algeta ASA Algeta announces positive preliminary bone marker results in a phase IIa study evaluating Alpharadin in breast cancer patients with bone metastases Algeta announces positive preliminary bone marker results in a phase IIa study evaluating Alpharadin in breast cancer patients with bone metastases
2011-06-06 07:57:00 Norway Algeta ASA Gjennombrudd for Algeta Gjennombrudd for Algeta
2011-06-06 07:00:00 Norway Algeta ASA Positive Outcome of Interim Analysis of pivotal Alpharadin study: Primary endpoint met in Phase III ALSYMPCA study Positive Outcome of Interim Analysis of pivotal Alpharadin study: Primary endpoint met in Phase III ALSYMPCA study
2011-06-01 08:00:00 Norway Algeta ASA Clinical analysis of Alpharadin to be presented at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO) Clinical analysis of Alpharadin to be presented at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO)
2011-05-12 07:01:00 Norway Algeta ASA Algeta Results for the First Quarter 2011 Algeta Results for the First Quarter 2011
1| 2| 3| 4|
Reklama

Prowadzisz działalność, wymieniasz walutę?

Zacznij oszczędzać! Nawet 1 500 zł przy wymianie 10 000 euro.

Fritz Exchange to bezpieczeństwo, błyskawiczna wymiana i najbardziej atrakcyjne kursy. więcej »

?
Zacznij wprowadzać nazwę interesującego Cie waloru
Giełda na skróty
SPÓŁKI GPW
  • Popularne
    na forum
  • Ostatnio
    oglądane
  • Mój
    portfel
Walor Kurs Zm.[%] Obrót
[mln]
PETROLINV 1,18 -4,07 5,03
VICTORIA 0,04 +0,00 0,00
ANTI 0,69 -1,43 0,02
ANALIZATOR Znajdź SPÓŁKĘ
WIĘCEJ KRYTERIÓW
?
Wprowadź listę symboli lub nazw walorów, które chcesz porównać na wykresie, rozdzielając je przecinkami.

W trakcie wypełniania pola, system będzie podpowiadał nazwy dostępnych walorów - możesz wybrać je z utworzonej listy.
Money analytics
money analytics